CatenaBio Analysis: $2M Raised
What is CatenaBio?
CatenaBio's CysTyr™ platform enables multi-payload conjugation of proteins, creating novel therapeutics for oncology and autoimmune disorders. The technology uses a novel C-Y Bond™ between cystine and tyrosine to attach diverse payloads with precise site control and high stability. Preclinical results show superior performance over current antibody-drug conjugates in solid tumors with high unmet medical needs.
Location
Berkeley, United States
Employees
11-50
Founded
2020
Funding Status
Seed
Product Features & Capabilities
- CysTyr™ conjugation platform
- Multi-Payload Conjugates (MPCs)
- C-Y Bond™ technology
- Therapeutic development for oncology and autoimmune disorders
Use Cases
Create dual-payload ADCs for solid tumors with high unmet needs; Develop novel therapeutics for autoimmune disorders; Generate stable conjugates with precise drug-to-antibody ratios; Enable attachment of complex payloads beyond small molecules; Improve stability to reduce off-target release in antibody-drug conjugates
Other Considerations
Presented at AACR Annual Meeting 2024; Selected to present at Berkeley Bio Startup Showcase @JPM 2024; Appointed new CBO and CSO in July 2023; Founded in 2020 based on UC Berkeley Francis and Doudna Labs technology; CysTyr platform enables attachment of multiple payloads at multiple sites with flexible DAR control
See something that needs updating? Suggest edits to this profile.